1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Innate Pharma S.A.

Innate Pharma S.A.

IPHYF
Innate Pharma S.A.US flagOther OTC
1.65
USD
- -
- -
154.94MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.32
0.02
0.34
1.04
0.6
1.36
1.03
0.71
0.15
0.62
0.62
0.16
0.03
Basic EPS, GAAP
-0.07
-0.39
-0.13
0.23
-0.89
0.05
-0.31
-0.81
-0.66
-0.73
-0.09
-0.61
-0.55
Free Cash Flow per Basic Share
-0.29
-0.41
3.75
-0.86
-1
-0.58
-0.46
-0.8
-0.75
-0.25
-0.63
-0.09
-0.39
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.88
1.41
1.34
1.6
1.49
2.61
2.76
1.97
1.35
0.68
0.64
0.11
-0.23
Tangible Book Value per Share
0.88
1.31
1.16
1.43
0.69
1.29
1.53
1.39
0.8
0.66
0.64
0.11
-0.23
Basic Weighted Avg Shares
39
50
53
54
54
59
67
79
80
80
84
81
90
Sales/Revenue/Turnover
12
1
18
56
33
80
69
56
12
50
52
13
3
Operating Margin (%)
-22.24
-2,201.43
-60.16
13.48
-122.53
6.44
2.29
1.92
-394.94
-33.13
-24.41
-408.65
-1,916.94
Depreciation Expense
1
2
3
3
4
7
17
57
5
45
1
2
5
Net Income, GAAP
-3
-20
-7
13
-48
3
-21
-64
-53
-58
-8
-49
-49
Effective Tax Rate (%)
- -
- -
- -
2.33
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-23.19
-2,166.15
-37.45
22.51
-148.28
3.82
-30.26
-113.94
-436.08
-117.19
-14.59
-391.97
-1,764.51
Working Capital
40
69
192
154
64
123
116
128
58
98
108
53
10
LT Debt
4
4
3
4
5
3
17
17
14
40
31
22
14
Total Equity
40
75
72
86
86
167
217
156
107
54
52
9
-22
Return on Invested Capital (%)
- -
- -
- -
8.44
- -
- -
0.75
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
15.25
- -
- -
-10.08
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-9.09
-34.19
-9.14
15.98
-56.22
2.41
-10.79
-34.27
-40.1
-71.91
-14.28
-162.91
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-39.79%
-102.71%
-345.69%
Free Cash Flow
33.58%
76.49%
379.07%
Net Income, GAAP
-99.17%
91.7%
-0.59%
Sales/Revenue/Turnover
36.64%
16.41%
-77.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
52
2024
- -
- -
- -
- -
13
2025
- -
- -
- -
- -
3

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.09
2024
- -
- -
- -
- -
-0.61
2025
- -
- -
- -
- -
-0.55

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jonathan E. Dickinson
Full Time Employees
163
Sector
Healthcare
Industry
Biotechnology
Address
117, Avenue de Luminy Marseille PA France 13009
IPO Date
Jun 9, 2015
CIK
0001598599
Website
innate-pharma.com
Similar Companies
Ocugen, Inc. (OCGN)
Synairgen plc (SNG.L)
Aprea Therapeutics, Inc. (APRE)
Onconova Therapeutics Inc. Warrants (ONTXW)
Pila Pharma AB (publ) (PILA.ST)
ReproCELL Incorporated (4978.T)
Business
Innate Pharma SA, a clinical-stage biotechnology company, develops immunotherapies that harness the innate immune system to treat cancer patients through antibody drug conjugates, monoclonal antibodies, and multi-specific NK cell engagers via its proprietary ANKET platform. Its lead pipeline candidates include IPH4502, a Nectin-4-targeted ADC for solid tumors; lacutamab, an anti-KIR3DL2 monoclonal antibody for advanced cutaneous T-cell lymphomas and peripheral T-cell lymphomas; and monalizumab, an anti-NKG2A antibody partnered with AstraZeneca for non-small cell lung cancer, with additional assets such as IPH5201 (anti-CD39, partnered with AstraZeneca), IPH5301 (anti-CD73), and the BCMA-targeted ANKET program with Sanofi for autoimmune indications. The company operates primarily in Europe and the United States, serving oncology patients with high unmet needs through collaborations with biopharmaceutical leaders including AstraZeneca, Sanofi, and research institutions. Founded in 1999 and headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma lists on Euronext Paris and Nasdaq. Recent developments include a €15 million equity investment from Sanofi in April 2025 amid ongoing BCMA ANKET partnership; FDA clearance for the TELLOMAK-3 trial of lacutamab; prioritization of IPH4502, lacutamab, and monalizumab with approximately 30% staffing reductions for resource focus; enrollment completion in AstraZeneca's Phase 3 PACIFIC-9 monalizumab trial, with data expected in second-half 2026; and advancement of preclinical ADCs leveraging innovative targets.

Company News

Company News APIChatGPT

  • businesswire.com

    Innate Pharma Announces Conference Call and Webcast

  • businesswire.com

    Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

  • businesswire.com

    Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

  • businesswire.com

    Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

  • businesswire.com

    Outcome of Innate Pharma's 2026 Annual General Meeting